0

Close
 
2022
Olanzapine Market

Olanzapine Market

by Application (Schizophrenia, Bipolar Disorder, Others), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

LS : Pharmaceuticals
Report Code: A15452
Oct 2022 | Pages: 229
Tables: 143
Charts: 58

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

Olanzapine Market Research, 2031

The global olanzapine market size was valued at $1.8 billion in 2021 and is projected to reach $2.2 billion by 2031, growing at a CAGR of 2.3% from 2022 to 2031. Olanzapine is an oral tablet used to treat schizophrenia, depression, and bipolar I disorder. It is available as a tablet and an orally disintegrating tablet, which dissolves fast in the mouth. The side effects associated with olanzapine are difficulty swallowing, headache, dizziness, feeling tired or restless, and drowsiness.

Olanzapine is also used with fluoxetine to treat depression in adults and children at least 10 years old who have bipolar I disorder. Olanzapine belongs to a group of medicines called antipsychotics and it works by affecting the naturally occurring chemical messengers in the brain (neurotransmitters), like dopamine and serotonin.

COVID-19 negatively affect the olanzapine market due to a decline in R&D activities and sales of olanzapine drug. In addition, fewer hospital visits for the treatment of schizophrenia disease negatively impacts the market growth.

Olanzapine Market

Growth of the olanzapine market size is driven by rise in the population with schizophrenia of various countries, such as China and Japan. As the global population grow, individuals do not receive complete nutrition for kids, which led to rise in prevalence of schizophrenia. In addition, increase in government support for healthcare infrastructure improvements further boosts the olanzapine market growth. Furthermore, rise in the dysfunctional behavior among population contribute toward the growth of the market. For instance, according to data published by World Health Organization (WHO), in June 2022, 1 in every 8 people in the world lives with a mental disorder.

Moreover, surge in initiatives taken by government to provide facilities for mental disorder patients contributes toward the growth of the market. However, high cost of olanzapine and side effects of olanzapine may hamper the growth of olanzapine market. In contrast, high growth potential in developing economies and increase in R&D activities and product approval are expected to provide the beneficial olanzapine market opportunity.

Impact of COVID-19

The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the globe. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. However, there has been a negative effect on the olanzapine industry due to decline in R&D activities and sales  olanzapine drug. In addition, less hospitals visits for treatment of schizophrenia disease negatively impacts the market growth. Furthermore, most of the clinical trials are postponed to avoid spread of infections, which slowdowns the drug development process. Thus, COVID-19 has significant negative impact on the olanzapine market. Moreover, availability of telemedicine (online service) to treat the diseases, led to steady growth of the olanzapine industry during COVID-19.

OLANZAPINE MARKET SEGMENTATION

The olanzapine market is segmented into application, route of administration, distribution channel, and region. By application, the market is categorized into schizophrenia, bipolar disorder, and others. By route of administration, it is bifurcated into oral and parenteral. By distribution channel, it is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

Depending on the application, the market is segmented into schizophrenia, bipolar disorder, and others. The schizophrenia segment dominated the global market in 2021. The factor which drives the growth of this segment include, a rise in incidences of mental illness. For instance, according to the National Institute of Mental Health (NIH) in the U.S., 52.9 million adults lived with mental illness in 2020. Thus, an increase in incidences of mental illness, which requires olanzapine medication as a treatment to treat the disease, propels market growth.

Olanzapine Market

On the basis of the route of administration, the market is bifurcated into oral and parenteral. The oral segment accounted for the largest revenue in 2021. This was attributed to the high adoption of oral drugs due to noninvasive, high patient compliance, convenient to handle, and not requiring any specific sterile conditions. For instance, Sun Pharmaceutical Industries Ltd. Provides oral olanzapine tablets. However, the parenteral segment is projected to register the highest CAGR during the olanzapine market forecast. This is attributed to advantages associated with parenteral routes, such as being suitable for unconscious patients, low concentration of drug required for administration, and shows better bioavailability.

Olanzapine Market

On the basis of distribution channels, the market is segmented into hospital pharmacies, drug stores & retail pharmacies and online providers. The drug stores & retail pharmacies segment accounted for the largest olanzapine market share in 2021. This was attributed to the availability of olanzapine drugs in drug stores and retail pharmacies.

However, the online providers segment is projected to register the highest CAGR during the forecast period. This is attributed to increasing the number of smartphone users and higher internet penetration to buy medicines. For instance, according to a report by Global System for Mobile Communications (GSMC), a global organization unifying the mobile ecosystem, in 2021, there were an estimated 5.3 billion unique mobile phone users, in which 4.2 billion population have active mobile phone internet connection. Furthermore, innovative marketing strategies, the introduction of new business models, and an upsurge in the pharmacies & wellness stores are anticipated to propel the growth of the segment.

Olanzapine Market

Region-wise, North America acquired a major olanzapine market share in 2021, owing to the increase in demand for olanzapine drugs due to the rise in the prevalence of schizophrenia in this region. However, Asia-Pacific is expected to witness the highest growth rate for the olanzapine market during the forecast period with the highest CAGR. This is attributed to increasing government initiatives to promote a healthy lifestyle. Moreover, the rise in the number of drug stores & retail pharmacies for olanzapine drugs in this region further boosts the market growth.

Olanzapine Market

 

The key market players profiled in the report include Alkermes, Apotex Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Torrent Power Ltd, and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the olanzapine market analysis from 2021 to 2031 to identify the prevailing olanzapine market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the olanzapine market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global olanzapine market trends, key players, market segments, application areas, and market growth strategies.

 Olanzapine Market Report Highlights

Aspects Details
Market Size By 2031 USD 2.2 billion
Growth Rate CAGR of 2.3%
Forecast period 2021 - 2031
Report Pages 229
By Application
  • Bipolar Disorder
  • Others
  • Schizophrenia
By Route of Administration
  • Oral
  • Parenteral
By Distribution Channel
  • Hospital Pharmacies
  • Drug stores and Retail Pharmacies
  • Online Providers
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Viatris, apotex inc., Torrent Group, Alkermes, Inc., Dr. Reddy's Laboratories Ltd., Novartis AG, Aurobindo Pharma Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited
 

  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: OLANZAPINE MARKET, BY APPLICATION

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Schizophrenia

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market share analysis by country

    • 4.3 Bipolar Disorder

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market share analysis by country

    • 4.4 Others

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market share analysis by country

  • CHAPTER 5: OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Oral

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market share analysis by country

    • 5.3 Parenteral

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market share analysis by country

  • CHAPTER 6: OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Hospital Pharmacies

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market share analysis by country

    • 6.3 Drug stores and Retail Pharmacies

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market share analysis by country

    • 6.4 Online Providers

      • 6.4.1 Key market trends, growth factors and opportunities

      • 6.4.2 Market size and forecast, by region

      • 6.4.3 Market share analysis by country

  • CHAPTER 7: OLANZAPINE MARKET, BY REGION

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 North America

      • 7.2.1 Key trends and opportunities

      • 7.2.2 North America Market size and forecast, by Application

      • 7.2.3 North America Market size and forecast, by Route of Administration

      • 7.2.4 North America Market size and forecast, by Distribution Channel

      • 7.2.5 North America Market size and forecast, by country

        • 7.2.5.1 U.S.
          • 7.2.5.1.1 Key market trends, growth factors and opportunities
          • 7.2.5.1.2 Market size and forecast, by Application
          • 7.2.5.1.3 Market size and forecast, by Route of Administration
          • 7.2.5.1.4 Market size and forecast, by Distribution Channel
        • 7.2.5.2 Canada
          • 7.2.5.2.1 Key market trends, growth factors and opportunities
          • 7.2.5.2.2 Market size and forecast, by Application
          • 7.2.5.2.3 Market size and forecast, by Route of Administration
          • 7.2.5.2.4 Market size and forecast, by Distribution Channel
        • 7.2.5.3 Mexico
          • 7.2.5.3.1 Key market trends, growth factors and opportunities
          • 7.2.5.3.2 Market size and forecast, by Application
          • 7.2.5.3.3 Market size and forecast, by Route of Administration
          • 7.2.5.3.4 Market size and forecast, by Distribution Channel

    • 7.3 Europe

      • 7.3.1 Key trends and opportunities

      • 7.3.2 Europe Market size and forecast, by Application

      • 7.3.3 Europe Market size and forecast, by Route of Administration

      • 7.3.4 Europe Market size and forecast, by Distribution Channel

      • 7.3.5 Europe Market size and forecast, by country

        • 7.3.5.1 Germany
          • 7.3.5.1.1 Key market trends, growth factors and opportunities
          • 7.3.5.1.2 Market size and forecast, by Application
          • 7.3.5.1.3 Market size and forecast, by Route of Administration
          • 7.3.5.1.4 Market size and forecast, by Distribution Channel
        • 7.3.5.2 France
          • 7.3.5.2.1 Key market trends, growth factors and opportunities
          • 7.3.5.2.2 Market size and forecast, by Application
          • 7.3.5.2.3 Market size and forecast, by Route of Administration
          • 7.3.5.2.4 Market size and forecast, by Distribution Channel
        • 7.3.5.3 UK
          • 7.3.5.3.1 Key market trends, growth factors and opportunities
          • 7.3.5.3.2 Market size and forecast, by Application
          • 7.3.5.3.3 Market size and forecast, by Route of Administration
          • 7.3.5.3.4 Market size and forecast, by Distribution Channel
        • 7.3.5.4 Italy
          • 7.3.5.4.1 Key market trends, growth factors and opportunities
          • 7.3.5.4.2 Market size and forecast, by Application
          • 7.3.5.4.3 Market size and forecast, by Route of Administration
          • 7.3.5.4.4 Market size and forecast, by Distribution Channel
        • 7.3.5.5 Spain
          • 7.3.5.5.1 Key market trends, growth factors and opportunities
          • 7.3.5.5.2 Market size and forecast, by Application
          • 7.3.5.5.3 Market size and forecast, by Route of Administration
          • 7.3.5.5.4 Market size and forecast, by Distribution Channel
        • 7.3.5.6 Rest of Europe
          • 7.3.5.6.1 Key market trends, growth factors and opportunities
          • 7.3.5.6.2 Market size and forecast, by Application
          • 7.3.5.6.3 Market size and forecast, by Route of Administration
          • 7.3.5.6.4 Market size and forecast, by Distribution Channel

    • 7.4 Asia-Pacific

      • 7.4.1 Key trends and opportunities

      • 7.4.2 Asia-Pacific Market size and forecast, by Application

      • 7.4.3 Asia-Pacific Market size and forecast, by Route of Administration

      • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

      • 7.4.5 Asia-Pacific Market size and forecast, by country

        • 7.4.5.1 Japan
          • 7.4.5.1.1 Key market trends, growth factors and opportunities
          • 7.4.5.1.2 Market size and forecast, by Application
          • 7.4.5.1.3 Market size and forecast, by Route of Administration
          • 7.4.5.1.4 Market size and forecast, by Distribution Channel
        • 7.4.5.2 China
          • 7.4.5.2.1 Key market trends, growth factors and opportunities
          • 7.4.5.2.2 Market size and forecast, by Application
          • 7.4.5.2.3 Market size and forecast, by Route of Administration
          • 7.4.5.2.4 Market size and forecast, by Distribution Channel
        • 7.4.5.3 India
          • 7.4.5.3.1 Key market trends, growth factors and opportunities
          • 7.4.5.3.2 Market size and forecast, by Application
          • 7.4.5.3.3 Market size and forecast, by Route of Administration
          • 7.4.5.3.4 Market size and forecast, by Distribution Channel
        • 7.4.5.4 Australia
          • 7.4.5.4.1 Key market trends, growth factors and opportunities
          • 7.4.5.4.2 Market size and forecast, by Application
          • 7.4.5.4.3 Market size and forecast, by Route of Administration
          • 7.4.5.4.4 Market size and forecast, by Distribution Channel
        • 7.4.5.5 South Korea
          • 7.4.5.5.1 Key market trends, growth factors and opportunities
          • 7.4.5.5.2 Market size and forecast, by Application
          • 7.4.5.5.3 Market size and forecast, by Route of Administration
          • 7.4.5.5.4 Market size and forecast, by Distribution Channel
        • 7.4.5.6 Rest of Asia-Pacific
          • 7.4.5.6.1 Key market trends, growth factors and opportunities
          • 7.4.5.6.2 Market size and forecast, by Application
          • 7.4.5.6.3 Market size and forecast, by Route of Administration
          • 7.4.5.6.4 Market size and forecast, by Distribution Channel

    • 7.5 LAMEA

      • 7.5.1 Key trends and opportunities

      • 7.5.2 LAMEA Market size and forecast, by Application

      • 7.5.3 LAMEA Market size and forecast, by Route of Administration

      • 7.5.4 LAMEA Market size and forecast, by Distribution Channel

      • 7.5.5 LAMEA Market size and forecast, by country

        • 7.5.5.1 Brazil
          • 7.5.5.1.1 Key market trends, growth factors and opportunities
          • 7.5.5.1.2 Market size and forecast, by Application
          • 7.5.5.1.3 Market size and forecast, by Route of Administration
          • 7.5.5.1.4 Market size and forecast, by Distribution Channel
        • 7.5.5.2 Saudi Arabia
          • 7.5.5.2.1 Key market trends, growth factors and opportunities
          • 7.5.5.2.2 Market size and forecast, by Application
          • 7.5.5.2.3 Market size and forecast, by Route of Administration
          • 7.5.5.2.4 Market size and forecast, by Distribution Channel
        • 7.5.5.3 South Africa
          • 7.5.5.3.1 Key market trends, growth factors and opportunities
          • 7.5.5.3.2 Market size and forecast, by Application
          • 7.5.5.3.3 Market size and forecast, by Route of Administration
          • 7.5.5.3.4 Market size and forecast, by Distribution Channel
        • 7.5.5.4 Rest of LAMEA
          • 7.5.5.4.1 Key market trends, growth factors and opportunities
          • 7.5.5.4.2 Market size and forecast, by Application
          • 7.5.5.4.3 Market size and forecast, by Route of Administration
          • 7.5.5.4.4 Market size and forecast, by Distribution Channel

  • CHAPTER 8: COMPANY LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Key developments

  • CHAPTER 9: COMPANY PROFILES

    • 9.1 Alkermes, Inc.

      • 9.1.1 Company overview

      • 9.1.2 Company snapshot

      • 9.1.3 Operating business segments

      • 9.1.4 Product portfolio

      • 9.1.5 Business performance

      • 9.1.6 Key strategic moves and developments

    • 9.2 apotex inc.

      • 9.2.1 Company overview

      • 9.2.2 Company snapshot

      • 9.2.3 Operating business segments

      • 9.2.4 Product portfolio

      • 9.2.5 Business performance

      • 9.2.6 Key strategic moves and developments

    • 9.3 Aurobindo Pharma Ltd

      • 9.3.1 Company overview

      • 9.3.2 Company snapshot

      • 9.3.3 Operating business segments

      • 9.3.4 Product portfolio

      • 9.3.5 Business performance

      • 9.3.6 Key strategic moves and developments

    • 9.4 Eli Lilly and Company

      • 9.4.1 Company overview

      • 9.4.2 Company snapshot

      • 9.4.3 Operating business segments

      • 9.4.4 Product portfolio

      • 9.4.5 Business performance

      • 9.4.6 Key strategic moves and developments

    • 9.5 Dr. Reddy's Laboratories Ltd.

      • 9.5.1 Company overview

      • 9.5.2 Company snapshot

      • 9.5.3 Operating business segments

      • 9.5.4 Product portfolio

      • 9.5.5 Business performance

      • 9.5.6 Key strategic moves and developments

    • 9.6 Sun Pharmaceutical Industries Limited

      • 9.6.1 Company overview

      • 9.6.2 Company snapshot

      • 9.6.3 Operating business segments

      • 9.6.4 Product portfolio

      • 9.6.5 Business performance

      • 9.6.6 Key strategic moves and developments

    • 9.7 Torrent Group

      • 9.7.1 Company overview

      • 9.7.2 Company snapshot

      • 9.7.3 Operating business segments

      • 9.7.4 Product portfolio

      • 9.7.5 Business performance

      • 9.7.6 Key strategic moves and developments

    • 9.8 Teva Pharmaceutical Industries Limited

      • 9.8.1 Company overview

      • 9.8.2 Company snapshot

      • 9.8.3 Operating business segments

      • 9.8.4 Product portfolio

      • 9.8.5 Business performance

      • 9.8.6 Key strategic moves and developments

    • 9.9 Novartis AG

      • 9.9.1 Company overview

      • 9.9.2 Company snapshot

      • 9.9.3 Operating business segments

      • 9.9.4 Product portfolio

      • 9.9.5 Business performance

      • 9.9.6 Key strategic moves and developments

    • 9.10 Viatris

      • 9.10.1 Company overview

      • 9.10.2 Company snapshot

      • 9.10.3 Operating business segments

      • 9.10.4 Product portfolio

      • 9.10.5 Business performance

      • 9.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 2. OLANZAPINE MARKET FOR SCHIZOPHRENIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 3. OLANZAPINE MARKET FOR SCHIZOPHRENIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 4. OLANZAPINE MARKET FOR BIPOLAR DISORDER, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 5. OLANZAPINE MARKET FOR BIPOLAR DISORDER, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 6. OLANZAPINE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 7. OLANZAPINE MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 8. GLOBAL OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 9. OLANZAPINE MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 10. OLANZAPINE MARKET FOR ORAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 11. OLANZAPINE MARKET FOR PARENTERAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 12. OLANZAPINE MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 13. GLOBAL OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 14. OLANZAPINE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 15. OLANZAPINE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 16. OLANZAPINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 17. OLANZAPINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 18. OLANZAPINE MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 19. OLANZAPINE MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 20. OLANZAPINE MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 21. NORTH AMERICA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 22. NORTH AMERICA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 23. NORTH AMERICA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 24. NORTH AMERICA OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 25. U.S. OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 26. U.S. OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 27. U.S. OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 28. CANADA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 29. CANADA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 30. CANADA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 31. MEXICO OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 32. MEXICO OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 33. MEXICO OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 34. EUROPE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 35. EUROPE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 36. EUROPE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 37. EUROPE OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 38. GERMANY OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 39. GERMANY OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 40. GERMANY OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 41. FRANCE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 42. FRANCE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 43. FRANCE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 44. UK OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 45. UK OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 46. UK OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 47. ITALY OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 48. ITALY OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 49. ITALY OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 50. SPAIN OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 51. SPAIN OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 52. SPAIN OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 53. REST OF EUROPE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 54. REST OF EUROPE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 55. REST OF EUROPE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 56. ASIA-PACIFIC OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 57. ASIA-PACIFIC OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 58. ASIA-PACIFIC OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 59. ASIA-PACIFIC OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 60. JAPAN OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 61. JAPAN OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 62. JAPAN OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 63. CHINA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 64. CHINA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 65. CHINA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 66. INDIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 67. INDIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 68. INDIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 69. AUSTRALIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 70. AUSTRALIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 71. AUSTRALIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 72. SOUTH KOREA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 73. SOUTH KOREA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 74. SOUTH KOREA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 75. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 76. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 77. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 78. LAMEA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 79. LAMEA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 80. LAMEA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 81. LAMEA OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 82. BRAZIL OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 83. BRAZIL OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 84. BRAZIL OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 85. SAUDI ARABIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 86. SAUDI ARABIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 87. SAUDI ARABIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 88. SOUTH AFRICA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 89. SOUTH AFRICA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 90. SOUTH AFRICA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 91. REST OF LAMEA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 92. REST OF LAMEA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
    TABLE 93. REST OF LAMEA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 94.ALKERMES, INC.: COMPANY SNAPSHOT
    TABLE 95.ALKERMES, INC.: OPERATING SEGMENTS
    TABLE 96.ALKERMES, INC.: PRODUCT PORTFOLIO
    TABLE 97.ALKERMES, INC.: NET SALES
    TABLE 98.ALKERMES, INC.: KEY STRATERGIES
    TABLE 99.APOTEX INC.: COMPANY SNAPSHOT
    TABLE 100.APOTEX INC.: OPERATING SEGMENTS
    TABLE 101.APOTEX INC.: PRODUCT PORTFOLIO
    TABLE 102.APOTEX INC.: NET SALES
    TABLE 103.APOTEX INC.: KEY STRATERGIES
    TABLE 104.AUROBINDO PHARMA LTD: COMPANY SNAPSHOT
    TABLE 105.AUROBINDO PHARMA LTD: OPERATING SEGMENTS
    TABLE 106.AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO
    TABLE 107.AUROBINDO PHARMA LTD: NET SALES
    TABLE 108.AUROBINDO PHARMA LTD: KEY STRATERGIES
    TABLE 109.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
    TABLE 110.ELI LILLY AND COMPANY: OPERATING SEGMENTS
    TABLE 111.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
    TABLE 112.ELI LILLY AND COMPANY: NET SALES
    TABLE 113.ELI LILLY AND COMPANY: KEY STRATERGIES
    TABLE 114.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
    TABLE 115.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
    TABLE 116.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
    TABLE 117.DR. REDDY'S LABORATORIES LTD.: NET SALES
    TABLE 118.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
    TABLE 119.SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
    TABLE 120.SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
    TABLE 121.SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
    TABLE 122.SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES
    TABLE 123.SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
    TABLE 124.TORRENT GROUP: COMPANY SNAPSHOT
    TABLE 125.TORRENT GROUP: OPERATING SEGMENTS
    TABLE 126.TORRENT GROUP: PRODUCT PORTFOLIO
    TABLE 127.TORRENT GROUP: NET SALES
    TABLE 128.TORRENT GROUP: KEY STRATERGIES
    TABLE 129.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
    TABLE 130.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
    TABLE 131.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
    TABLE 132.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES
    TABLE 133.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
    TABLE 134.NOVARTIS AG: COMPANY SNAPSHOT
    TABLE 135.NOVARTIS AG: OPERATING SEGMENTS
    TABLE 136.NOVARTIS AG: PRODUCT PORTFOLIO
    TABLE 137.NOVARTIS AG: NET SALES
    TABLE 138.NOVARTIS AG: KEY STRATERGIES
    TABLE 139.VIATRIS: COMPANY SNAPSHOT
    TABLE 140.VIATRIS: OPERATING SEGMENTS
    TABLE 141.VIATRIS: PRODUCT PORTFOLIO
    TABLE 142.VIATRIS: NET SALES
    TABLE 143.VIATRIS: KEY STRATERGIES

  • LIST OF FIGURES

  • FIGURE 1.OLANZAPINE MARKET SEGMENTATION
    FIGURE 2.OLANZAPINE MARKET,2021-2031
    FIGURE 3.OLANZAPINE MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.OLANZAPINE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.OLANZAPINE MARKET,BY APPLICATION,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF SCHIZOPHRENIA OLANZAPINE MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF BIPOLAR DISORDER OLANZAPINE MARKET,2021-2031(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS OLANZAPINE MARKET,2021-2031(%)
    FIGURE 16.OLANZAPINE MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ORAL OLANZAPINE MARKET,2021-2031(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF PARENTERAL OLANZAPINE MARKET,2021-2031(%)
    FIGURE 19.OLANZAPINE MARKET,BY DISTRIBUTION CHANNEL,2021(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES OLANZAPINE MARKET,2021-2031(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES OLANZAPINE MARKET,2021-2031(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS OLANZAPINE MARKET,2021-2031(%)
    FIGURE 23.OLANZAPINE MARKET BY REGION,2021
    FIGURE 24.U.S. OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 25.CANADA OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 26.MEXICO OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 27.GERMANY OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 28.FRANCE OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 29.UK OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 30.ITALY OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 31.SPAIN OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 32.REST OF EUROPE OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 33.JAPAN OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 34.CHINA OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 35.INDIA OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 36.AUSTRALIA OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 37.SOUTH KOREA OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 38.REST OF ASIA-PACIFIC OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 39.BRAZIL OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 40.SAUDI ARABIA OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 41.SOUTH AFRICA OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 42.REST OF LAMEA OLANZAPINE MARKET,2021-2031($MILLION)
    FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 47.COMPETITIVE DASHBOARD
    FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 49.ALKERMES, INC..: NET SALES ($MILLION)
    FIGURE 50.APOTEX INC..: NET SALES ($MILLION)
    FIGURE 51.AUROBINDO PHARMA LTD.: NET SALES ($MILLION)
    FIGURE 52.ELI LILLY AND COMPANY.: NET SALES ($MILLION)
    FIGURE 53.DR. REDDY'S LABORATORIES LTD..: NET SALES ($MILLION)
    FIGURE 54.SUN PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)
    FIGURE 55.TORRENT GROUP.: NET SALES ($MILLION)
    FIGURE 56.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)
    FIGURE 57.NOVARTIS AG.: NET SALES ($MILLION)
    FIGURE 58.VIATRIS.: NET SALES ($MILLION)

 
 

The global olanzapine market is expected to exhibit high growth potential attributable to factors such as rise in incidence of mental disorders and surge in awareness toward mental health disorders. However, side effects such as weight gain, increase in cholesterol levels and risk of diabetes caused due to antipsychotic drugs hamper the market growth.

Olanzapine is used for the treatment of schizophrenia and other associated mental disorders. It is also used in combination with an antidepressant to treat the depression that cannot be controlled with other drugs.

Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to rise in incidences of schizophrenia, the presence of key players for manufacturing & developing of schizophrenia drug such as olanzapine, and surge in number of hospitals in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in prevalence of schizophrenia and increase in investments for manufacturing olanzapine during the forecast period.
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The market value of olanzapine market in 2031 is $2,220.82 million

A. Top companies such as Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, Dr. Reddy’,s Laboratories Ltd., and Novartis AG held a high market position in 2021. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Schizophrenia is the most influencing segment in olanzapine market which is attributed to rise in prevalence of schizophrenia due to change in lifestyle in people.

A. The base year is 2021 in olanzapine market.

A. Olanzapine is an atypical antipsychotic drug, primarily used to treat schizophrenia and bipolar disorder.

A. The major factor that fuels the growth of the olanzapine market are rise in prevalence of schizophrenia globally, rise in the number of mental disorder clinics and improvement in healthcare infrastructure.

A. The forecast period for olanzapine market is 2022 to 2031

A. The total market value of olanzapine market is $1,765.50 million in 2021.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Olanzapine Market

Start reading instantly.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)

  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers